Advertisement

Topics

AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights

16:01 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Six patients with life-threatening S. aureus or P. aeruginosa infections treated to date with AB-SA01 or AB-PA01 under expanded access in the U.S. and Australia Second clinical institution to treat pa...

Other Sources for this Article

At the Company:
AmpliPhi Biosciences
Matthew Dansey
(858) 800-4869
md@ampliphibio.com
or
Investor Relations:
Westwicke Partners
Robert H. Uhl
(858) 356-5932
robert.uhl@westwicke.com
or
Media:
Russo Partners, LLC
David Schull or Maggie Beller
(212) 845-4271
David.Schull@RussoPartnersLLC.com
Maggie.Beller@RussoPartnersLLC.com

NEXT ARTICLE

More From BioPortfolio on "AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

MRSA (methicillin-resistant Staphylococcus aureus)
MRSA (methicillin-resistant Staphylococcus aureus) is a family of bacteria with resistance to one or more major antibiotics. There are currently 17 different strains of MRSA. Two particular strains, EMRSA15 and EMRSA16  account for 96% of MRSA blood...